Browse studies

Find your next paid study

1 recruiting study matching your filters

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibito…

Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more

Revolution Medicines, Inc.NCT06162221